Patient-derived Tumor Xenografts
Patient-derived Tumor Xenografts - Related Videos
08:03
Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
0 Views •
Cited by 59 •
2015
This manuscript details a method used to generate prostate cancer patient derived xenografts (PDXs) from circulating tumor cells (CTCs). The generation of PDX models from CTCs provides an alternative experimental model to study prostate cancer; the most commonly diagnosed tumor and a frequent cause of death from cancer in men.
03:56
Tumor Enzymatic Digestion: A Procedure to Generate Tumor Cell Suspension from Patient-derived Xenograft Cancer Mouse Models
0 Views •
2023
This video describes the procedure to obtain tumor cell suspension from patient-derived xenograft or PDX cancer mouse models. Small animal models provide an expeditious, reproducible, and adaptable platform to study tumor progression and different metastatic...
03:21
Zebrafish Patient-Derived Xenograft (zPDX): A Cancer Model
0 Views •
2023
This video describes the technique to create a zebrafish patient derived xenograft model. In the sample protocol, we assess the efficiency of the drugs Gemcitabine and Navitoclax on the pancreatic tumor xenograft model.
07:44
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
0 Views •
2025
The development of orthotopic pediatric brain tumor models requires meticulous precision, using a stereotaxic device to implant cancer cells precisely. The methodology presented here outlines the steps involved in preparing brain tumor cells, performing intracranial injections, and implementing a post-operative monitoring system to assess brain tumor engraftment.
09:53
Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies
0 Views •
Cited by 18 •
2016
We describe a method for stable labeling of patient-derived xenografts (PDXs) with lentiviral particles expressing green-fluorescent protein and luciferase reporters. This method allows for tracking the growth of PDXs at the primary site, as well as detecting spontaneous and experimental metastases using in vivo imaging systems.
FAQs
Patient-derived tumor xenografts can retain clinically relevant features because the implanted material comes directly from a patient’s tumor rather than from a long-established cell-line model. Investigators can subsequently examine tumor growth, histology, and molecular characteristics in the graft. This continuity makes the model useful for studying how preserved tumor properties relate to treatment response in cancer research.
The host’s immunodeficiency removes the effective immune response against human tissue that would otherwise interfere with engraftment. As a result, implanted patient material can establish and expand sufficiently for investigators to follow tumor growth and assess histology, molecular characteristics, or treatment response. The host condition is therefore a functional requirement for maintaining the model.
Because the model can preserve clinically relevant tumor features, it is suited to examining tumor heterogeneity rather than only average behavior in a uniform laboratory population. Comparing growth, molecular characteristics, histology, or treatment responses among grafts can reveal differences within patient-derived material. This makes the approach valuable when varied tumor properties may influence drug efficacy or resistance.
Establishing a patient-derived tumor xenograft begins with tumor-derived material, either fragments or cells, followed by implantation into an immunodeficient animal, usually a mouse. After implantation, the graft is allowed to establish and expand, then monitored for growth and characterized by histology or molecular analysis. Treatment studies can be incorporated to evaluate response.
Researchers use these models to evaluate drug efficacy and investigate resistance in a tumor context that can retain patient-linked characteristics. Treatment response is assessed alongside tumor growth and other model readouts, allowing investigators to connect therapeutic exposure with changes in the graft. Such experiments can inform investigation of potential patient-specific therapies, although the model requires time and specialized resources.
In cancer research, the main translational value of patient-derived tumor xenografts is their potential to connect laboratory findings with clinical decision-making. Their tumor-associated histological and molecular characteristics provide context for interpreting treatment responses, while measurements of growth and resistance add outcome information. This combination supports investigation of patient-specific therapies alongside conventional cell-line models.